Generation and CRISPR/Cas9 editing of transformed progenitor B cells as a pseudo-physiological system to study DNA repair gene function in V(D)J recombination

J Immunol Methods. 2017 Dec:451:71-77. doi: 10.1016/j.jim.2017.08.007. Epub 2017 Sep 4.

Abstract

Antigen receptor gene assembly is accomplished in developing lymphocytes by the V(D)J recombination reaction, which can be separated into two steps: DNA cleavage by the recombination-activating gene (RAG) nuclease and joining of DNA double strand breaks (DSBs) by components of the nonhomologous end joining (NHEJ) pathway. Deficiencies for NHEJ factors can result in immunodeficiency and a propensity to accumulate genomic instability, thus highlighting the importance of identifying all players in this process and deciphering their functions. Bcl2 transgenic v-Abl kinase-transformed pro-B cells provide a pseudo-physiological cellular system to study V(D)J recombination. Treatment of v-Abl/Bcl2 pro-B cells with the Abl kinase inhibitor Imatinib leads to G1 cell cycle arrest, the rapid induction of Rag1/2 gene expression and V(D)J recombination. In this system, the Bcl2 transgene alleviates Imatinib-induced apoptosis enabling the analysis of induced V(D)J recombination. Although powerful, the use of mouse models carrying the Bcl2 transgene for the generation of v-Abl pro-B cell lines is time and money consuming. Here, we describe a method for generating v-Abl/Bcl2 pro-B cell lines from wild type mice and for performing gene knock-out using episomal CRISPR/Cas9 targeting vectors. Using this approach, we generated distinct NHEJ-deficient pro-B cell lines and quantified V(D)J recombination levels in these cells. Furthermore, this methodology can be adapted to generate pro-B cell lines deficient for any gene suspected to play a role in V(D)J recombination, and more generally DSB repair.

Keywords: CRISPR/Cas9-mediated gene knock-out; Nonhomologous end joining (NHEJ); Recombination-activating gene (RAG) endonuclease; V(D)J recombination; v-Abl transformed pro-B cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • CRISPR-Associated Proteins / genetics*
  • CRISPR-Associated Proteins / metabolism
  • CRISPR-Cas Systems*
  • Cell Line, Transformed
  • Clustered Regularly Interspaced Short Palindromic Repeats*
  • DNA Breaks, Double-Stranded*
  • DNA End-Joining Repair
  • DNA-Binding Proteins / genetics
  • DNA-Binding Proteins / metabolism
  • G1 Phase Cell Cycle Checkpoints / drug effects
  • Gene Editing / methods*
  • Genotype
  • Homeodomain Proteins / genetics
  • Homeodomain Proteins / metabolism
  • Imatinib Mesylate / pharmacology
  • Mice, Inbred C57BL
  • Oncogene Proteins v-abl / antagonists & inhibitors
  • Oncogene Proteins v-abl / genetics
  • Oncogene Proteins v-abl / metabolism
  • Phenotype
  • Precursor Cells, B-Lymphoid / drug effects
  • Precursor Cells, B-Lymphoid / metabolism*
  • Precursor Cells, B-Lymphoid / pathology
  • Protein Kinase Inhibitors / pharmacology
  • Proto-Oncogene Proteins c-bcl-2 / genetics
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Recombinational DNA Repair* / drug effects

Substances

  • CRISPR-Associated Proteins
  • DNA-Binding Proteins
  • Homeodomain Proteins
  • Oncogene Proteins v-abl
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins c-bcl-2
  • Rag2 protein, mouse
  • Bcl2 protein, mouse
  • RAG-1 protein
  • Imatinib Mesylate